Gatechompol, Sivaporn
Kittanamongkolchai, Wonngarm
Ketloy, Chutitorn
Prompetchara, Eakchai
Thitithanyanont, Arunee
Jongkaewwattana, Anan
Buranapraditkun, Supranee
Alameh, Mohamad-Gabriel
Ubolyam, Sasiwimol
Sophonphan, Jiratchaya
Apornpong, Tanakorn
Kerr, Stephen
Kamarulzaman, Adeeba
Siwamogsatham, Sarawut
Kroon, Eugène
Puthanakit, Thanyawee
Patarakul, Kanitha
Palaga, Tanapat
Wijagkanalan, Wassana
Carpenter, Alexis
Hong, Lina
Weissman, Drew
Ruxrungtham, Kiat http://orcid.org/0000-0001-7348-2352
,
Funding for this research was provided by:
Chulalongkorn University (764002-HE04)
Article History
Received: 28 March 2022
Accepted: 17 October 2022
First Online: 14 November 2022
Competing interests
: In accordance with the University of Pennsylvania policies and procedures and our ethical obligations as researchers, we report that Drew Weissman is named on patents that describe the use of nucleoside-modified mRNA as a platform to deliver therapeutic proteins and vaccines. We have disclosed those interests fully to the University of Pennsylvania, and we have in place an approved plan for managing any potential conflicts arising from licensing of our patents. The other authors declare no competing interests.
Free to read: This content has been made available to all.